Home Halogens {3-[(9Z)-2-chloro-9H-thioxanthen-9-ylidene]propyl}dimethylamine

{3-[(9Z)-2-chloro-9H-thioxanthen-9-ylidene]propyl}dimethylamine

CAS No.:
113-59-7
Catalog Number:
AG00785B
Molecular Formula:
C18H18ClNS
Molecular Weight:
315.8602
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
25mg
99%(HPLC)
In Stock USA
United States
$53
- +
1g
98%
In Stock USA
United States
$63
- +
5g
98%
In Stock USA
United States
$188
- +
10g
98%
In Stock USA
United States
$313
- +
25g
98%
In Stock USA
United States
$600
- +
Product Description
Catalog Number:
AG00785B
Chemical Name:
{3-[(9Z)-2-chloro-9H-thioxanthen-9-ylidene]propyl}dimethylamine
CAS Number:
113-59-7
Molecular Formula:
C18H18ClNS
Molecular Weight:
315.8602
MDL Number:
MFCD00869180
IUPAC Name:
(3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
InChI:
InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7-
InChI Key:
WSPOMRSOLSGNFJ-AUWJEWJLSA-N
SMILES:
CN(CC/C=C\1/c2ccccc2Sc2c1cc(Cl)cc2)C
EC Number:
204-032-8
UNII:
9S7OD60EWP
NSC Number:
18720
Properties
Complexity:
381  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
1  
Exact Mass:
315.085g/mol
Formal Charge:
0
Heavy Atom Count:
21  
Hydrogen Bond Acceptor Count:
2  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
315.859g/mol
Monoisotopic Mass:
315.085g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
28.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
5.2  
Literature
Title Journal
Why are most phospholipidosis inducers also hERG blockers? Archives of toxicology 20171201
A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryotic cell 20130201
Intrathecal chlorprothixene, cis(z)-flupenthixol, chlorpromazine and fluphenazine for prolonged spinal blockades of sensory and motor functions in rats. European journal of pharmacology 20121015
Shape-based reprofiling of FDA-approved drugs for the H₁ histamine receptor. Journal of medicinal chemistry 20120823
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry 20120524
Real-time 2D separation by LC × differential ion mobility hyphenated to mass spectrometry. Analytical and bioanalytical chemistry 20120301
Solvent dependence of the photophysical properties of 2-chlorothioxanthone, the principal photoproduct of chlorprothixene. Photochemistry and photobiology 20110501
Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. European journal of clinical pharmacology 20100901
[Incomplete about anticholinergic syndrome]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20100520
[A woman with known anxiety, depression and alcohol abuse]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20100225
Non-antibiotics reverse resistance of bacteria to antibiotics. In vivo (Athens, Greece) 20100101
Diagnosis and treatment of conduct disorder related to frontal lobe syndrome in a 16-year-old girl. Medicina (Kaunas, Lithuania) 20100101
Unassisted smothering in a pillow. International journal of legal medicine 20091101
Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorganic & medicinal chemistry letters 20090115
Photophysics and photochemistry of z-chlorprothixene in acetonitrile. Photochemistry and photobiology 20090101
Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. Medicina (Kaunas, Lithuania) 20090101
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry 20081009
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). Journal of medicinal chemistry 20080612
Increase of risperidone concentration under chlorprothixene comedication--a case report. Pharmacopsychiatry 20080501
Sensitive determination of phenylephrine and chlorprothixene at poly(4-aminobenzene sulfonic acid) modified glassy carbon electrode. Talanta 20080215
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. Journal of medicinal chemistry 20080124
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. No to shinkei = Brain and nerve 20060601
Searching for new antimalarial therapeutics amongst known drugs. Chemical biology & drug design 20060601
Microsphere-based protease assays and screening application for lethal factor and factor Xa. Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Sensitive spectrophotometric methods for quantitative determination of chlorprothixene in pharmaceutical dosage form. Pakistan journal of pharmaceutical sciences 20060401
A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. Journal of medicinal chemistry 20050421
Determination of chlorprothixene and amitryptyline hydrochlorides by UV-derivative spectrophotometry and UV-solid-phase spectrophotometry. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20050301
In-patient psychiatric-psychotherapeutic treatment of mothers with a generalized anxiety disorder--does the co-admission of their children influence the treatment results? A prospective, controlled study. Wiener klinische Wochenschrift 20041130
Chemiluminescent analysis of the antioxidant and immunomodulation effects of several psychotropic drugs on peritoneal macrophages. Luminescence : the journal of biological and chemical luminescence 20040101
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). Journal of medicinal chemistry 20030703
Gamma-hydroxybutyrate versus chlorprothixene/phenobarbital sedation in children undergoing MRI studies. Klinische Padiatrie 20030101
[Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20030101
Simultaneous LC determination of some antidepressants combined with neuroleptics. Journal of pharmaceutical and biomedical analysis 20020701
Separation of cis- and trans-isomers of thioxanthene and dibenz[b,e]oxepin derivatives on calixarene- and resorcinarene-bonded high-performance liquid chromatography stationary phases. Journal of chromatography. A 20020301
Chlorpromazine-induced cholestatic liver disease with ductopenia. Ceskoslovenska patologie 20010701
Clozapine and weight gain. The American journal of psychiatry 20010501
Effect of some psychotropic drugs and a barbiturate on mycoplasmas. International journal of antimicrobial agents 20000401
Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. The Journal of pharmacology and experimental therapeutics 19991101
Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 19980701
Biologically active conformers of phenothiazines and thioxanthenes. Further evidence for a ligand model of dopamine D2 receptor antagonists. Journal of medicinal chemistry 19930723
Polyneuropathy caused by chlorprothixene. Acta psychiatrica Scandinavica 19920301
Effect of selected neuroleptic agents and stereo-isomeric analogues on virus and eukaryotic cells. Pharmacology & toxicology 19910501
A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. The Israel journal of psychiatry and related sciences 19910101
Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide. Acta psychiatrica Scandinavica 19900201
Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. European journal of pharmacology 19871110
The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. Acta pathologica, microbiologica, et immunologica Scandinavica. Section B, Microbiology 19861201
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group. Psychopharmacology 19860101
SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models. Life sciences 19851223
[Chlorprothixene-induced central anticholinergic syndrome (author' transl)]. Der Anaesthesist 19810601
The pathophysiology of acute renal failure after chlorprothixene overdosage. Acta medica Scandinavica 19810101
Seven cases of somnambulism induced by drugs. The American journal of psychiatry 19790701
[The extrapyramidal symptoms in the combination of lithium long-term lithium therapy with nortriptyline. A case report on the formation of a pathogenesis hypothesis]. Der Nervenarzt 19760101
Drug-induced dystonia. The American journal of psychiatry 19750501
Chlorprothixene therapy for herpes zoster neuralgia. Southern medical journal 19740701
Inhibition of ejaculation by chlorpromazine. The Journal of nervous and mental disease 19710501
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy. The Psychiatric quarterly 19670101
Drug-induced extrapyramidal symptoms: their incidence and treatment. The American journal of psychiatry 19670101
Properties